Therapy Areas: Devices
Guyer Named Board Chairman at Visus Therapeutics
3 November 2021 - - US-based clinical-stage pharmaceutical company Visus Therapeutics Inc has appointed ophthalmology and industry expert David Guyer, M.D. as the chairman of the board after serving as an advisor since the company's inception, and life sciences veteran Ted Danse as the head of business development, the company said.

Serving as the chairman of Visus Therapeutics' board of directors, Dr. Guyer brings more than 30 years of ophthalmic drug development experience as chief executive officer, venture capitalist and academician.

Currently a venture partner at SV Health Investors, he has led both public and private biotech companies, several of which he founded or co-founded, and was a professor and chairman of the Department of Ophthalmology at New York University School of Medicine.

Dr. Guyer developed and commercialized the first anti-VEGF (vascular endothelial growth factor) drug for macular degeneration as the co-founder and chief executive officer at Eyetech Pharmaceuticals.

He has taken two companies public, managed numerous mergers and acquisitions, and served on approximately 20 company boards.

As head of business development, Danse will play a leading role in identifying and executing strategic partnerships and collaborations.

A seasoned life sciences executive, Danse has held executive leadership roles at multiple start-ups as well as large corporate entities in life sciences, with a focus on biopharmaceuticals, recombinant drug delivery, implantable medical devices and durable medical equipment.

Previously, Danse was chief executive officer of Neurotech, a company now in late-stage trials for the treatment of macular telangiectasia.

Prior to that, he was responsible for taking ISTA Pharmaceuticals public in 2000. He also held various senior leadership positions at Allergan, including president of the Asia-Pacific Region where he was responsible for establishing high-growth, profitable business operations in Asia.

Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world.

With offices in Seattle, Washington, and Irvine, California, its lead clinical candidate is Brimochol, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia.

In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration.

Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a specialist in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.
Login
Username:

Password: